AnGes, Inc. (TYO:4563)
48.00
0.00 (0.00%)
Jun 3, 2026, 3:30 PM JST
AnGes Revenue
AnGes had revenue of 203.00M JPY in the quarter ending March 31, 2026, with 20.12% growth. This brings the company's revenue in the last twelve months to 908.00M, up 29.90% year-over-year. In the year 2025, AnGes had annual revenue of 874.00M with 35.93% growth.
Revenue (ttm)
908.00M
Revenue Growth
+29.90%
P/S Ratio
20.95
Revenue / Employee
16.21M
Employees
56
Market Cap
19.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 874.00M | 231.00M | 35.93% |
| Dec 31, 2024 | 643.00M | 491.00M | 323.03% |
| Dec 31, 2023 | 152.00M | 85.00M | 126.87% |
| Dec 31, 2022 | 67.00M | 3.00M | 4.69% |
| Dec 31, 2021 | 64.00M | 25.00M | 64.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.81B |
| ReproCELL | 2.23B |
| Japan Tissue Engineering | 2.18B |
| Immuno-Biological Laboratories | 1.00B |
| Stella Pharma | 323.00M |
| Cuorips | 212.00M |
| Nano Holdings | 174.00M |
| CellSeed | 161.00M |